Key Facts updated Jan 2017
*This non-GAAP amount excludes significant upfront and milestone payments for business development transactions and other specified R&D items.
OPDIVO®, $4.9 billion
ELIQUIS®, $4.9 billion
ORENCIA®, $2.5 billion
SPRYCEL®, $2.0 billion
YERVOY®, $1.2 billion
BARACLUDE®, $1.1 billion
SUSTIVA® franchise, $729 million
REYATAZ® franchise, $698 million
Hepatitis C franchise, $406 million
Please click on the product links to see the Full Prescribing Information for BARACLUDE®, DAKLINZA™,ELIQUIS®, EMPLICITI™, OPDIVO®, ORENCIA®, REYATAZ®, SPRYCEL®, SUSTIVA®, and YERVOY®, including Boxed WARNINGS for BARACLUDE®, ELIQUIS®, and Boxed WARNINGS for YERVOY® regarding immune-mediated adverse reaction.
Bristol-Myers Squibb Corporate B-roll
This B-roll includes a collection of footage of Bristol-Myers Squibb's campus, corporate signage, research and development, and manufacturing facilities.
Usage Rights & Restrictions
This media asset is free for editorial broadcast, print, online and radio use. It is restricted for other purposes.